Author:
Llop-Guevara Alba,Porras Mónica,Cendón Carla,Di Ceglie Irene,Siracusa Francesco,Madarena Federica,Rinotas Vagelis,Gómez Lluís,van Lent Peter L.,Douni Eleni,Chang Hyun Dong,Kamradt Thomas,Román Juan
Funder
Seventh Framework Programme (BE)
Innovative Medicines Initiative
Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy,Rheumatology
Reference64 articles.
1. Paula FS, Alves JD. Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. Biol Targets Therapy. 2014;8:1–12.
2. Hammaker D, Firestein GS. “Go upstream, young man”: lessons learned from the p38 saga. Ann Rheum Dis. 2010;69:77–82.
3. Foster JG, Blunt MD, Carter E, Ward SG. Inhibition of PI3K signaling spurs New therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies. Pharmacol Rev. 2012;64(4):1027–54.
4. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–97.
5. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, et al. Targeting interleukin-15 in patients with rheumatoid arthritis - a proof-of-concept study. Arthritis Rheum. 2005;52(9):2686–92.
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献